search
Back to results

Utilization of Platelet Gel for Treatment of Diabetic Foot Ulcers

Primary Purpose

Diabetic Foot Ulcers

Status
Completed
Phase
Phase 1
Locations
Iran, Islamic Republic of
Study Type
Interventional
Intervention
Platelet Gel
Placebo
Sponsored by
Royan Institute
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diabetic Foot Ulcers focused on measuring Platelet gel, diabetic foot ulcer, umbilical cord blood

Eligibility Criteria

30 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • History of at least 4 weeks hospitalization
  • Uncontrolled diabetes
  • ejection fraction > 30%

Exclusion Criteria:

  • mechanical origin for wound
  • history of infectious, systemic diseases, Immune deficiency and coagulation disorders

Sites / Locations

  • Royan Institute

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

platelet rich plasma

Placebo

Arm Description

The patients with diabetic foot ulcer who receive PG treatment.

The patients with diabetic foot ulcer who receive placebo.

Outcomes

Primary Outcome Measures

pain
Evaluation the pain reduction by VAS measurement in patients with peripheral artery Disease.
ABI
Evaluation the Ankle Brakial Index (ABI) in patients 3 months after PG utilization.

Secondary Outcome Measures

Quality of life
Evaluation the quality of life by SF36 measurement in patients with PAD.

Full Information

First Posted
May 7, 2014
Last Updated
December 3, 2015
Sponsor
Royan Institute
search

1. Study Identification

Unique Protocol Identification Number
NCT02134132
Brief Title
Utilization of Platelet Gel for Treatment of Diabetic Foot Ulcers
Official Title
Utilization of Umbilical Cord Blood-derived Platelet Gel for Treatment of Diabetic Foot Ulcers,a Randomized Double Blind Clinical Trial
Study Type
Interventional

2. Study Status

Record Verification Date
November 2011
Overall Recruitment Status
Completed
Study Start Date
January 2012 (undefined)
Primary Completion Date
March 2014 (Actual)
Study Completion Date
April 2014 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Royan Institute

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Diabetes is a multiorgan disease and considered a major health problem in different societies. One of the complications the pain particularly in the extremities resulting from a process known as diabetic foot ulcer. The diabetic patients are subjected to many complications because of foot ulcers, many of them like as chronic wound disease or pressure ulcers (bed sore). Routinely used medical measures for diabetic foot ulcers are depended to nursing care and take too long until pain relief. Among many tested materials and works for wound healing such as debridement, tissue oxygenation, and skin transplantation, platelet-derived compounds are allocated the pivotal position between investigators to tissue regeneration and shortening the wound healing process. Many of platelet components are procured from platelet rich plasma (PRP) from whole blood donation. Furthermore, it requires to an additional purification step to diminish the volume and facilitate handling in some studies. It means that platelet concentrates (PCs) may be obtained leading to more concentrated platelets in lower volume. Two types of granules in platelet is responsible for storage of many useful and different growth factors: dense or delta and alpha granules. Platelet-derived growth factors have the ability to growth and differentiation of numerous cells. Also, the antibacterial effect of these growth factors has been reported. To better efficacy and comfortable utilization of platelet, it is feasible to form the platelet gel and then apply on wound sites. This study is a double blind randomized controlled trial to evaluate the positive effects of umbilical cord blood-derived platelet gel in 244 patients with diabetic foot ulcers.
Detailed Description
In this study all qualified patients (based on the inclusion and exclusion criteria) were randomly allocated into three study groups by a Stratified Permuted Block randomization method: group A received platelet rich plasma gel, group B (placebo) received platelet poor plasma gel, and group C received lubricant gel. All of the patients underwent a standard long protocol for knee osteoarthritis. All patients with diabetic foot ulcer are selected.On average,in each instance, the amount of platelets in the peripheral bloodis4 to6 times the baseline level. Group A (interventional): application of 20-30mL of gel from platelet rich plasma (PRP) Group B (placebo): application of 20-30mL of gel from platelet poor plasma (PRP) Group C (control): application of 20-30 mL of lubricant gel (used typically for sonography)

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetic Foot Ulcers
Keywords
Platelet gel, diabetic foot ulcer, umbilical cord blood

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
30 (Actual)

8. Arms, Groups, and Interventions

Arm Title
platelet rich plasma
Arm Type
Active Comparator
Arm Description
The patients with diabetic foot ulcer who receive PG treatment.
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
The patients with diabetic foot ulcer who receive placebo.
Intervention Type
Biological
Intervention Name(s)
Platelet Gel
Intervention Description
Application of platelet gel in patients suffering from diabetic foot ulcers.
Intervention Type
Other
Intervention Name(s)
Placebo
Intervention Description
The patients with Diabetic foot ulcer who receive placebo instead of PL Gel.
Primary Outcome Measure Information:
Title
pain
Description
Evaluation the pain reduction by VAS measurement in patients with peripheral artery Disease.
Time Frame
3 months
Title
ABI
Description
Evaluation the Ankle Brakial Index (ABI) in patients 3 months after PG utilization.
Time Frame
3 months
Secondary Outcome Measure Information:
Title
Quality of life
Description
Evaluation the quality of life by SF36 measurement in patients with PAD.
Time Frame
3months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
30 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: History of at least 4 weeks hospitalization Uncontrolled diabetes ejection fraction > 30% Exclusion Criteria: mechanical origin for wound history of infectious, systemic diseases, Immune deficiency and coagulation disorders
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Hamid Gourabi, PhD
Organizational Affiliation
Head of Royan Institute
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Nasser Aghdami, MD,PhD
Organizational Affiliation
Head of regenerative medicine department &cell therapy center of Royan Institute
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Behnam Molavi, MD
Organizational Affiliation
Department of vascular & Trauma Surgery of Sina Hospital
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Seyedeh Esmat Hosseini, Bs
Organizational Affiliation
Department of Regenerative Medicine & cell therapy of Royan Institute
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Alireza Goodarzi, MSc
Organizational Affiliation
Department of Regenerative Medicine of Royan Institute
Official's Role
Principal Investigator
Facility Information:
Facility Name
Royan Institute
City
Tehran
Country
Iran, Islamic Republic of

12. IPD Sharing Statement

Links:
URL
http://Royaninstitute.org
Description
Related Info

Learn more about this trial

Utilization of Platelet Gel for Treatment of Diabetic Foot Ulcers

We'll reach out to this number within 24 hrs